Even the popular press is excited about recent developments involving anti-CD3, a potential type 1 therapy with strong ties to UCSF. In a recent issue of FORBES Magazine, senior editor Robert Langreth reveals the long history of anti-CD3 -- a monoclonal antibody that stops beta cell destruction.
Thanks to a generous gift made possible by a family whose lives have been impacted by type 1 diabetes, the Mary B. Olney MD / KAK Chair in Pediatric Diabetes and Clinical Research has been awarded to Steve Gitelman, MD, Director of the UCSF Pediatric Diabetes Program.
While leading the Department of Biochemistry and Biophysics and the Hormone Research Institute, William J. Rutter, PhD helped UCSF to make some of its most important contributions in biotechnology -- including the cloning of the genes for insulin and human growth hormone. It was these discoveries that spurred the creation of the world’s first biotech company, Genentech Inc., and Chiron Corp., the company Dr. Rutter co-founded.
To take a promising drug to market, it costs on average $500 million. Academic research institutions such as UCSF excel in conducting basic research and early stage human clinical trials, however, for cost reasons it is important that promising therapies are picked up by private industry.
Inflammation is a biological process driven by the immune system to help the body react to infection, irritation or other injury -- and help the body to repair itself. Researchers in the UCSF Helen Diller Family Comprehensive Cancer Center have learned that the mast cell, a cell of the immune system, plays an important role in inflammation.
Nearly two-thirds of US adults are overweight – fueling the twin epidemic of obesity and type 2 diabetes in this country. Allison Xu, an Assistant Professor who was trained at Stanford and joined the UCSF Diabetes Center in 2006, is focused on understanding how the central nervous system regulates body weight and glucose levels.
McGraw Hill has just published “Diabetes DeMystified: A Self-Teaching Guide”, written by our very own UCSF physician and clinical researcher, Umesh Masharani, M.D.
Have you or a loved one ever been frustrated by how your diabetes has been managed in a hospital setting? Thanks to a team of clinicians led by Robert Rushakoff, MD and Umesh Masharani, MD, UCSF has tackled this problem head on by putting in place new insulin management systems for patients with diabetes being treated in UCSF hospitals.
A team of researchers including Miguel Ramalho-Santos, Ph.D., a UCSF Fellow and member of the Diabetes Center, have reported that they have improved a technique for genetically reprogramming mouse cells to become embryonic stem cells. By over-expressing a combination of genes in mouse skin cells, the mouse cells begin to lose their adult functions and function like they did in their embryonic state.
Feroz Papa, M.D., Ph.D. was awarded a prestigious New Innovator Award, one of only 29 investigators nationwide who received this award. The NIH created this new award to help stimulate highly innovative research and support promising new investigators.
Longtime Diabetes Center volunteers, Bobbie and Michael Wilsey, approached Diabetes Center Director, Dr. Jeffrey Bluestone, and Diabetes Teaching Center Medical Director, Dr. Martha Nolte, to express interest in supporting UCSF’s diabetes clinical efforts. All parties agreed that the most effective use of their $250,000 gift would be to establish a clinical diabetes fellowship program in the adult clinic.
When Anastasia Mavropoulos, PhD arrived at UCSF from her home in Belgium, she had already achieved an impressive record of success in studying pancreas development. Her animal model of choice in Belgium? The zebrafish – an organism that has been studied extensively in developmental biology because its embryos develop rapidly, progressing from eggs to larvae in under three days.
UCSF can count another young research star among its ranks. Michael McManus, PhD was recently awarded a $1.75 million research grant by the W.M. Keck Foundation. Each year, the foundation supports promising scientists in the country pursuing breakthrough biomedical research. McManus is rapidly becoming an expert in microRNAs - the so called “dark matter” of the genome.